Search Results - "Jhund, P.S"

ELEVATED HIGH SENSITIVITY TROPONIN IS ASSOCIATED WITH POORER OUTCOMES IN PATIENTS WITH HEART FAILURE AND REDUCED BY SACUBITRIL/VALSARTAN by Pandey, S, Jhund, P.S, Claggett, B, Solomon, S.D, Hagege, A.A, Prescott, M.F, Rouleau, J.L, Swedberg, K, Zile, M.R, McMurray, J.J, Packer, M

Get full text

Assessing the impact of cardiovascular events on health-related quality of life outcomes in DAPA-HF by McEwan, P, Qin, L, Jhund, P.S, Docherty, K.F, McMurray, J.J.V

“…Abstract Background Heart failure (HF) patients are at increased risk of cardiovascular (CV) events, including hospitalisation for HF (hHF), myocardial…”
Get full text

Evaluating the key predictors of health-related quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial by McEwan, P, McMurray, J.J.V, Jhund, P.S, Docherty, K.F, Qin, L

“…Abstract Background The DAPA-HF trial demonstrated that dapagliflozin was superior to placebo at preventing cardiovascular death and hospitalisation for heart…”
Get full text

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial by Mackenzie, Isla S, Ford, Ian, Nuki, George, Hallas, Jesper, Hawkey, Christopher J, Webster, John, Ralston, Stuart H, Walters, Matthew, Robertson, Michele, De Caterina, Raffaele, Findlay, Evelyn, Perez-Ruiz, Fernando, McMurray, John J V, MacDonald, Thomas M, Aziz, J., Dobson, G., Doney, A.S.F., Flynn, R.W.V., Furnace, J., Grieve, J.W.K., Guthrie, G., Jamieson, D., Jennings, C.G., Kean, S., Lund, L.C., McConnachie, A., Pigazzani, F., Riches, P.L., Rix Hanson, M., Rogers, A, Rooke, E.D.M., Thomson, J., Warren, M., Wetherall, K., Wilson, R., Hall, C.P., Maseri, A., Bird, H.A., Murray, G., Dear, J.W., Petrie, M., MacDonald, M., Jhund, P.S., Connolly, E., Murphy, D.J., Paul, N., Olsson, A., Koskinen, P.T., Fuat, A., Foster, A., Saywood, W., Barr, R.J., McConnachie, L., Wilson, L.F., Larsen Rasmussen, L., McGinnis, A.R., Birrell, H., Keiller, M., Bremner, I.S., Forbes, G.J., Dumbleton, J.S., Rhodes, J., Waller, T.

“…Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the…”
Get full text

Interleukin-6 and outcomes in patients recently hospitalized with heart failure and preserved ejection fraction by Mooney, L, Jackson, C.E, McConnachie, A, Myles, R, McMurray, J.J.V, Petrie, M.C, Jhund, P.S, Lang, N.N

“…Abstract Introduction Inflammation may play a role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Interleukin-6 (IL-6) is an…”
Get full text

P3001Stable rates of first hospitalisation for infective endocarditis with no improvement in survival: a population level study of Scotland from 1996-2014 by Campbell, R., Petrie, M.C., McMurray, J.J.V., Jhund, P.S.

Get full text

Reduced cognitive function is associated with poor outcomes in HFpEF: a post hoc analysis from PARAGON-HF by Dewan, P, Jhund, P.S, Anand, I.S, Desai, A.S, Pieske, B, Rizkala, A.R, Shah, S.J, Shi, V.C, Van Veldhuisen, D.J, Zannad, F, Zile, M.R, Solomon, S.D, McMurray, J.J.V

“…Abstract Background Little is known about the prevalence and consequences of cognitive impairment in patients with heart failure and preserved ejection…”
Get full text

Age- and Sex-Specific Rates of Heart Failure and other Adverse Cardiovascular Outcomes in Systemic Sclerosis by Sun, G.L, Yafasova, A, Andersson, C, McMurray, J.J.V, Jhund, P.S, Docherty, K.F, Faurschou, M, Nielsen, C.T, Shams-Eldin, A, Gislason, G.H, Torp-Pedersen, C, Fosboel, E.L, Koeber, L, Butt, J.H

“…Abstract Background Age at disease onset and sex appear to modify the disease course in patients with systemic sclerosis (SSc). Although patients with SSc have…”
Get full text

Effect of sacubitril/valsartan on cognitive function in patients with HFpEF: a prespecified analysis of PARAGON-HF by Dewan, P, Jhund, P.S, Anand, I.S, Desai, A.S, Gong, J, Lefkowitz, M.P, Pieske, B, Rizkala, A.R, Shah, S.J, Van Veldhuisen, D.J, Zannad, F, Zile, M.R, Solomon, S.D, McMurray, J.J.V

“…Abstract Background A theoretical concern has been raised about detrimental effects of sacubitril/valsartan (sac/val) on cognitive function as neprilysin is…”
Get full text

Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF by Kristensen, S.L, Docherty, K.F, Jhund, P.S, Bengtsson, O, Demets, D.L, Inzucchi, S.E, Kober, L, Kosiborod, M.N, Langkilde, A.M, Martinez, F.A, Ponikowski, P, Sabatine, M.S, Sjostrand, M, Solomon, S.D, McMurray, J.J.V

“…Abstract Background Hyperkalaemia often limits the use of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure and reduced ejection…”
Get full text

The effect of dapagliflozin across the spectrum of baseline risk: a post-hoc analysis of DAPA-HF by Docherty, K.F, Jhund, P.S, Bengtsson, O, Demets, D.L, Inzucchi, S.E, Kober, L, Kosiborod, M.N, Langkilde, A.M, Lindholm, D, Martinez, F.A, Ponikowski, P, Sabatine, M.S, Sjostrand, M, Solomon, S.D, McMurray, J.J.V

“…Abstract Background In DAPA-HF, compared to placebo, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, reduced the risk of cardiovascular…”
Get full text

Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions by Welsh, P, Welsh, C, Celis-Morales, C.A.C, Brown, R, Ferguson, L.D, Gray, S, Mark, P, Lewsey, J, Lyall, D.M, Gill, J.M.R, Pell, J, Jhund, P.S, De Lemos, J.A, Willeit, P, Sattar, N

“…Abstract Background Lipoprotein (a) (Lp(a)) measurement may help guide CVD risk prediction, is thought to be causal in several CVD outcomes, and phase 3…”
Get full text

The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF by Dewan, P, Jhund, P.S, Bengtsson, O, Demets, D.L, Inzucchi, S.E, Kober, L, Kosiborod, M.N, Langkilde, A.M, Lindholm, D, Martinez, F.A, Ponikowski, P, Sabatine, M.S, Sjostrand, M, Solomon, S.D, McMurray, J.J.V

“…Abstract Background Chronic obstructive pulmonary disease (COPD) is an important comorbidity in HFrEF, associated with worse outcomes and suboptimal treatment…”
Get full text

Prognostic value of ambulatory blood pressure values in elderly patients with heart failure. Results of the DICUMAP study by Camafort, M., Jhund, P.S., Formiga, F., Castro-Salomó, A., Arévalo-Lorido, J.C., Sobrino-Martínez, J., Manzano, L., Díez-Manglano, J., Aramburu, Ó., Montero Pérez-Barquero, M., Babkowski, Miguel Camafort, Carlos Arévalo Lorido, José, Martínez, Javier Sobrino, Espinosa, Luis Manzano, Luis Arias Jiménez, José, Cerezo, Jorge Gómez, Francisco, Jorge, Manglano, Jesús Díez, Bodas, Oscar Aramburu, Amorós, Jordi Grau, Peréz-Barquero, Manuel Montero, Cortada, Gerard Torres, Vila, Joan Carles Trullàs, Manuel Varela Aguilar, José, Martínez de las Cuevas, Gonzalo, Ordóñez, Fernando Salgado, Bailón, Manuel Méndez, Pizá, Nuria Ribas

“…Ambulatory blood pressure monitoring (ABPM) has demonstrated value in the prognostic assessment of hypertensive patients with heart failure (HF) with or…”
Get full text